The role of biomarkers in glioblastoma diagnosis: Will tissue diagnosis still be needed?

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Molecular abnormalities in gliomas that carry significant diagnostic, therapeutic, and prognostic implications are increasingly recognized including IDH mutation, 1p/19q chromosome co-deletion, and MGMT promoter methylation. These and other biomarkers can also be increasingly detected by imaging or blood and body fluid analysis. This raises the question of whether tissue diagnosis is still needed in this molecular era. We will review current knowledge of biomarkers in gliomas, non-invasive methods for assessing these biomarkers, and the pros and cons of biomarker assessment vs. tissue diagnosis.

Original languageEnglish (US)
Title of host publicationGlioblastoma Multiforme: Symptoms, Diagnosis, Therapeutic Management and Outcome
PublisherNova Science Publishers, Inc.
Pages123-134
Number of pages12
ISBN (Print)9781634832892, 9781634832731
StatePublished - Jul 1 2015

Keywords

  • 1p/19q
  • Biomarker
  • Biopsy
  • Glioblastoma
  • IDH
  • MGMT
  • Spectroscopy
  • Texture

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The role of biomarkers in glioblastoma diagnosis: Will tissue diagnosis still be needed?'. Together they form a unique fingerprint.

  • Cite this

    Parney, I. F., Malucelli, A., Gustafson, M., & Dietz, A. B. (2015). The role of biomarkers in glioblastoma diagnosis: Will tissue diagnosis still be needed? In Glioblastoma Multiforme: Symptoms, Diagnosis, Therapeutic Management and Outcome (pp. 123-134). Nova Science Publishers, Inc..